Telostin Tablet 40/5 mg
Telmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.
MFDS item code 202001838 · Approved 2020.03.17
This product's status changed to Approval withdrawn on 2024.12.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension; improvement of dyslipidemia; reduction of cardiovascular disease risk and inhibition of atherosclerosis progression
This medication is used for patients who need to take telmisartan and rosuvastatin simultaneously. Telmisartan helps reduce the risk of myocardial infarction, stroke, and cardiovascular disease mortality in adults with hypertension and a high risk of cardiovascular disease. Rosuvastatin lowers cholesterol levels in patients with hypercholesterolemia, particularly familial hypercholesterolemia and mixed dyslipidemia, delays the progression of atherosclerosis, and reduces cardiovascular disease risk. It is also used to lower the risk of stroke, myocardial infarction, and revascularization in high-risk patients with elevated high-sensitivity C-reactive protein levels. By administering these two components together, it effectively controls blood pressure and blood lipids, improving cardiovascular health.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of its components, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amount of each active ingredient) for convenience.
This medication can cause serious harm to the fetus and newborn during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by individuals allergic to this drug or its ingredients, pregnant or potentially pregnant women, or nursing mothers. Patients with severe hepatic impairment or issues with bile excretion need to exercise caution when taking this medication. Patients with a history of muscle disorders or severe kidney dysfunction should also be cautious when taking this medication. Caution is necessary when administering this drug to the elderly, patients with high potassium levels, or those with mild hepatic impairment. If symptoms such as myalgia, muscle weakness, or muscle cramps occur, consult a physician immediately, and muscle enzyme levels may need to be checked if necessary. This medication requires regular monitoring of liver function tests, and if there is a significant increase in liver enzymes, it should be discontinued. Due to its blood pressure-lowering effects, dizziness or hypotension may occur, so special caution is needed for those taking high doses of diuretics or with low blood volume. As there may be interactions with other drugs, inform healthcare professionals of all medications being taken, particularly when combined with drugs that may increase muscle toxicity. This medication has not been sufficiently proven to be safe and effective in children and is not recommended for pediatric use. Overdose may lead to hypotension, dizziness, and deterioration of kidney function, requiring immediate medical attention. During treatment, be cautious of dizziness or drowsiness when driving or operating dangerous machinery. This medication should be stored out of reach of children and should not be transferred to other containers.
Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, increased ALT, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver damage, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated CK levels, reduced hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, hypotension, tachycardia, bradycardia, acute kidney failure, shock, loss of consciousness, liver dysfunction, jaundice, anaphylaxis-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, myopathy, myositis, myalgia, increased CK, constipation, increased AST, numbness, chest discomfort, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, arthralgia, fatigue, sensory disturbances, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is safe to store the medication at room temperature between 1 to 30 degrees Celsius, avoiding extremes of heat or cold.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.